Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2025
      • CERI Press Releases 2022
      • CERI Press Releases 2021 >
        • Press Releases 2019 >
          • Press Releases 2020
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Cancer Education
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

The Journal of Simplified Cancer Research (JSCR) - New Article Release

Tweet
Follow @canceredinst

FDA grants Breakthrough Therapy Designation to Rindopepimut (Rintega)
By Ms. Elana Meer and Ayguen Sahin, M.Sc., Ph.D. | CERI Research Team
More details of this article can be found in our JSCR - March 2015 Issue


Update: Data Safety and Monitoring Board Recommends Celldex’s Study of RINTEGA® in Newly Diagnosed Glioblastoma Be Discontinued


FDA grants Breakthrough Therapy Designation to Rindopepimut (Rintega)Glioblastoma multiforme (GBM) - the most common brain cancer in adults
EGFRvIII and Glioblastoma

Glioblastoma consists of malignant (cancerous, growing) cells that form tumors from the star shaped glial cells, called astrocytes, which make up the supportive tissue of the brain. Glioblastoma (GBM) is a Grade IV Astrocytoma (as it arises from astrocyte cells) and is the most common, most deadly, and most aggressive type of brain tumor in adults. Despite multimodal treatment with surgery, radiotherapy, and chemotherapy (temozolomide), the survival time is usually between16 to 19 months. Similar to other cancers that arise from their tissue of origin, since Glioblastomas evolve from normal brain cells, the tumors can easily live within normal brain tissue, hidden from immune recognition and response. Similarly, due to their access to the vast network of blood vessels in the brain, and due to the fast production rate of these abnormal cells, Glioblastomas are highly cancerous and can spread throughout the brain quickly. Similarly, Glioblastomas are particularly difficult to treat because they are made up of many different cell types, which may respond differently to different types of therapies.

EGFRvIII is a tumor specific oncogene, a gene that may cause or amplify cancer growth. It is expressed in about 30% of glioblastoma tumors and is a mutation in the epidermal growth factor receptor, EGFR, a protein that increases cancer cell growth. Expression of EGFRvIII not only correlates with increased tumor growth in a single cell, but can also release microvesicles, fragments of membrane that contain EGFRvIII to nearby cells, further increasing tumor growth on an amplified level. Since EGFRvIII is associated with extremely poor outcomes, is mostly found in tumor cells, and is absent in normal tissues, it is a good target for treatment in the brain.

Picture
Rindopepimut

Rindopepimut (Rintega(R)) is an immunotherapy treatment under investigation, which works by targeting EGFRvIII, and reducing its ability to contribute to cancer growth. Rindopepimut is a peptide vaccine that binds to the corresponding 13-amino acid (molecules that make up proteins) “mutant vIII epitope,” which is connected to a carrier protein, KLH (for antibody production), which stimulates the immune system. Peptide vaccines are rapidly cycled and degraded in the body and therefore have minimal deleterious side effects. Peptides are naturally occurring biological molecules, which are made up of short chains of amino acids bonded together by peptide bonds (amine bonds). This peptide vaccine Rindopepimut, consists of using a peptide from the original pathogen, the cancer producing tumor in this case, to stimulate an immune response to fight the tumor. With the three Phase 2 trials of Rindopepimut (ACTIVATE, ACT II, and ACTIII) that have been carried out, the vaccine has been shown to inhibit the growth of EGFRvIII- expressing tumors in mouse models, suggesting that Rindopepimut has the capacity to improve both overall survival, and average survival without any progression of tumors. The vaccine seemingly initiates such a large immune response that 67% of patients who received Rindopepimut injectionss for 3 months or longer showed no visible expression of EGFRvIII.  In addition, a Phase 3 study is underway, ACT IV, in newly diagnosed GBM, and a Phase 2 study, called ReACT for recurrent GBM patients. These studies are showing promising results, with noticeable increases in immune responses and health outcomes after just 3-4 months. These developments represent exciting steps in a process for immunotherapy to play a greater role in improving health outcomes, and especially for enabling immunotherapy treatment in brain cancer.

FDA Breakthrough Therapy Designation

As Rindopepimut has shown improvement in clinical outcomes over available therapy options, the FDA intends to speed up the development and review process of this drug through a “Breakthrough Therapy Designation.” The Breakthrough Therapy designation aims to accelerate the progress, analysis and review of Rindopepimut, which has the capacity to make huge advances in the treatment of such a severe and life threatening condition such as GBM.
Glioblastoma
Oncogenes and EGFRvIII
Immunotherapy
Development of treatments for glioblastoma

Resources:

Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study [published online ahead of print January 13, 2015]. Neuro Oncol. pii: nou348.

Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288-2294.

Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962-6970.

Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466.

Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247-4254.

Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.

Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324-333.

Reardon D, Schuster J, Tran D, et al. ReACT: A phase II study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma. Oral presentation, Society for Neuro-Oncology Meeting, November 2014.

http://www.onclive.com/web-exclusives/fda-grants-rindopepimut-breakthrough-designation-for-egfrviii-positive-glioblastoma/3#sthash.dNpf3u1t.dpuf

http://www.onclive.com/web-exclusives/fda-grants-rindopepimut-breakthrough-designation-for-egfrviii-positive-glioblastoma/2

http://ir.celldex.com/releasedetail.cfm?ReleaseID=897618

http://www.neuros.net/es/images/glioblastoma_multiforme_RM.gif
The Journal of Simplified Cancer Research (JSCR) is the official journal of Cancer Research Simplified. For only $4.99 per monthly issue, [or a discounted $49.99 per year], you can gain digital access to straightforward information and articles on cancer news, diagnosis, prevention, treatment, and clinical trials. Fill out the form, make your payment, and you'll receive your copy right in your inbox! To get your copy now on The Journal of Simplified Cancer Research (JSCR) page.

    Help us to serve you better!

Submit

Yes, I'd like to help CERI continue saving lives!
Become an 'Empowered Lifeline Supporter' with $20/month which is $0.66 per day!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Picture
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2025 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®